AnaptysBio peanut allergy treatment drug received good news to clinical phase 2b promotion March 29, 2018 Source: Sina Pharmaceutical After a positive data from a small proof-of-concept study, AnaptysBio, a San Diego-based biotechnology company, has decided to turn to AB020, a drug that treats peanut allergy, to Phase 2b clinical trials. However, previous trial scales and company analysis of the data left questions such as the strength of the results and the effects of anti-IL-33 antibodies. The researchers recruited 20 patients who were classified as moderate to severe peanut allergy and were randomized to receive a single dose of ANB020 or a three-in-one placebo. Of the 15 patients who received the ANB020 treatment group, 7 were tolerant to a cumulative dose of 500 mg of peanut protein for 14 days. The baseline mean tolerance was 229 mg. In the placebo group, 2 of the 5 subjects tolerated the 500 mg dose on day 14. This is equivalent to a 47% and 40% non-strong response rate from placebo. However, the results of AnaptysBio's analysis are clearly better. AnaptysBio removed 2 patients (both of whom were responders) from the placebo group and 2 patients from the treatment group (they showed mild symptoms at baseline). The results from the exclusion of 4 patients in the analysis were more noticeable, with 46% of the patients in the treatment group responding, compared with 0% in the placebo group. The researchers believe that these data are not affected by the confounding effects of patients with mild allergies and can more accurately reflect the impact of ANB020, but it has not eliminated all doubts. Analysts at Jefferies, a well-known investment bank on Wall Street, wrote an explanation of the analysis. "The goal is to screen out mild patients through a history of allergies. It is now clear that past allergic reactions are not current. Perfect predictive metrics. The ruling of patients with mild to moderate-severe categories is entirely at the discretion of the blind-selected investigator using the PRACTALL protocol, which is consistent with the practice model of most American allergy experts." AnaptysBio stands out from the POC trial, and the data in this trial gives it confidence to enter the larger multi-dose clinical 2b trial phase. However, even though ANB020 has achieved positive results in patients with large differences in patient use, the clinical prospects and business prospects of ANB020 remain uncertain until AnaptysBio's competitive drugs with Aimmune and DBV Technologies are included in the competitive landscape. AnaptysBio's share price rose 11% in after-hours trading. (Sina Pharmaceutical Compilation / Bernardo) Article, picture reference source: AnaptysBio plans phase 2b peanut allergy trial after taking positives from POC data pull out sofa bed,Sofa Beds,single sofa bed,double sofa bed Guangzhou LoPhiDa Co.Ltd , https://www.guangdongwidinlsa.com